Angi Gillen

Looking forward to attending #ASH2024 this year. Let's connect and I can share with you how TD2 can support your next trial. 🔗https://hubs.li/Q02YXgqv0 #HematologyOncology #ClinicalTrials #OncologyCRO #BloodCancerResearch #DrugDevelopment #PrecisionOncology #ClinicalTrialSolutions

1

Excited to share the latest feature in our "Partnering Spotlight" series, where we share some of the connections we are building to foster scientific innovation in healthcare. In this edition, our very own Neha Kaushal sits down with Daniel Anderson, Professor of Chemical Engineering at MIT, to discuss the potential of innovative #mRNA applications in vaccines and novel treatments for genetic diseases. Check out the video to learn more about our collaboration! https://lnkd.in/eHwpyjeY #vaccines #immunoscience

40

1 Comment

What an interesting read on the shift from traditional patient recruitment methods in rare disease! Learn more about how to optimize patient-driven site engagement in my team member’s blog: https://bit.ly/4eHoBn4

3

🌟 Best of #ASMS2024 🌟 Fintiede Solutions is thrilled to share the groundbreaking advancements unveiled by Evosep at the #ASMS2024 conference in Anaheim! Evosep continues to push the boundaries in the field of proteomics, introducing innovations that are set to transform research and clinical diagnostics. 🔬 Key Innovations Announced: Fully Automated Workflows: - Capable of processing over 500 plasma samples per day. - Maximizes efficiency and minimizes manual intervention. - Ideal for accelerating drug discovery and supporting large-scale translational research. - Reduces cost per sample and environmental impact. Whisper™ Zoom Methods: - Enhances scalability and sensitivity for detailed and accurate proteomic analyses. - Unlocks the ability to detect low-abundant proteins and identify novel biomarkers. - Facilitates deeper biological insights into disease pathways. Evosep Biolabs: Center of Excellence for High Throughput Proteomics: - Specializes in high-throughput proteomics with automated sample preparation. - Offers access to state-of-the-art LC-MS/MS workflows and expert assay development. - Provides scalable capacity for outsourcing proteomics research projects. 🏆 Impact and Vision: Evosep's innovations are designed to make clinical proteomics 100x more robust and 10x faster, revolutionizing the landscape of proteomics research. These advancements are particularly aimed at accelerating drug discovery and enhancing proteomics-based diagnostics, ultimately improving patient care. We are proud to be part of this journey and look forward to the incredible breakthroughs these technologies will enable in the near future. #Evosep #Proteomics #ASMS2024 #ScientificInnovation #DrugDiscovery #TranslationalResearch #Biomarkers #ClinicalDiagnostics #automation #whisper

2

🌟 Clinical Tips from the 20th Annual California Cancer Consortium Conference 2024 🌟 Reflecting on key takeaways from this year's conference, where experts shared groundbreaking insights in cancer research and treatment: 🔬 Expansion Cohorts in Early Phase Clinical Trials: Valuable or Not? 📝 How to Submit a Clinical Letter of Intent (LOI) to NCI/CTEP 🫁 Advances in Limited and Extensive Stage Small Cell Lung Cancer 💡 New Biomarkers in Breast Cancer ⚡ Novel Targets in Hematologic Malignancies These sessions highlighted cutting-edge advancements and strategies shaping the future of oncology. Excited to see where these innovations will lead! #CaliforniaCancerConsortium #CancerResearch #ClinicalTrials #SmallCellLungCancer #BreastCancer #HematologicMalignancies #Oncology #ClinicalTips #MedicalInnovation #NCI #CancerCare Primo Lara Timothy Synold Jonathan Riess Paul Frankel Percy Ivy Tycel Phillips

7

Jennifer A. Woyach discusses congress insights from ASH 2024: https://lnkd.in/dSvEVgV4 In this interview she: • Summarizes BTK mutations and their impact on CLL treatment with BTKi • Adresses the impact of toxicity-related BTKi treatment discontinuation on the overall condition of CLL patients • Discusses combination therapy of BTK- and BCL-2 inhibitors in TN CLL patients The full memo inHaematology ASH 2024 SPECIAL ISSUE is coming soon! #ASH24 #Haematology #Hematology #CLL #Research

7

🏆 The first novel MOA approved in this space in decades....the US FDA approves, Bristol Myers Squibb's non-dopamine #Cobenfy (fmr Karuna Therapeutics). 🔬 An M1 and M4 muscarinic receptor dual agonist, KarXT 🧠 From a #strategic perspective, stemming from the Karuna acquisition, for BMS this bolsters and diversifies its neurology portfolio. This new option plusses up the #competitivelandscape in schizophrenia, and with the #efficacy and #tolerability profile, will likely be of keen interest to prescribers. 🤔 Any #predictions as to the uptake at this critical launch phase? https://lnkd.in/eaBw7C_d #BMS #Schizophrenia #Neurology #Neuropsychiatry #Pharma #Healthcare

2

The fourth quarter of 2024 is critical for the biotech industry, with 5 major FDA approval decisions on the horizon. These upcoming verdicts could impact everything from treatments for #cancer to #rarediseases 🧬 Stay ahead of the latest in #biotech and learn how these #FDA decisions could shape the future of healthcare.

12

🚀 Biotech Q3 Scorecard: 19 Stock-Moving Events to Watch! 📊 Exciting times ahead in the biotech world! Here are key developments to keep on your radar: Alnylam Pharmaceuticals vutrisiran vs BridgeBio acoramidis for ATTR-CM: ESC presentation in August Novo Nordisk's monlunabant for obesity: Phase 2 results (watch Skye Bioscience Inc. and Corbus, LLC too!) Viridian Therapeutics, Inc.'s VRDN-001 for thyroid eye disease: Phase 3 readout in September Sage Therapeutics' Sage-324 for essential tremor: Mid-stage study results Apellis Pharmaceuticals' Empaveli for kidney diseases: Phase 3 VALIANT study results early Q3 Eli Lilly and Company's bimagrumab for obesity: Phase 2 results mid-year UCB and Biogen's dapirolizumab for lupus: Phase 3 results Neurocrine Biosciences's NBI-1117568 for schizophrenia: Phase 2 results Elevation Oncology's EO-3021 for gastric/pancreatic cancers: Data update Plus: • AstraZeneca's Imfinzi FDA panel (July 25) • Potential approvals for Alzheimer's drugs: Eisai US/Biogen's Leqembi (EU) • Multiple FDA decisions including Gilead Sciences, Regeneron, Syndax Pharmaceuticals, Roche, and Bristol Myers Squibb 🔬 The biotech sector is buzzing with potential breakthroughs. Which company or development are you most excited about? Share your thoughts below! 👇 #Biotech #PharmaTrends #ClinicalTrials #DrugDevelopment

5

🌐 The Lynx.MD team is heading to San Diego for DIA 2024. Drug discovery is a complex, lengthy process. DIA brings together the life sciences community to discuss innovations accelerating advancements, bringing therapies to care faster. Reach out to the Lynx.MD team, including Collin Labar, on LinkedIn to learn more about how our partners are using Lynx.MD’s rich structured and unstructured data sets to find insights addressing medical affairs and market access. See you at #DIA2024! 🌟 #Data #Research

17

From an accelerated approval, Bristol Myers Squibb's KRAS-inh #KRAZATI obtains the nod for colorectal cancer (with Eli Lilly and Company's Erbitux (cetuximab)) https://lnkd.in/eRFiV9Fw "GlobalData recently predicted that the market for KRAS-targeting drugs in oncology could reach $4 billion by 2029, with Lumakras and Krazati accounting for around $1.4 billion of that total. Morningstar analyst Damien Conover said after the CRC approval that Krazati could become a $1 billion product, justifying BMS’ takeover of Mirati" 📈 As a #strategic milestone and growth potential standpoint, the treatment is only one of two on the market, representing a significant advancement in the treatment of this disease, particularly for patients with a specific genetic mutation. #BMS #Krazati #KRASinhibitors #CRC #Oncology #ColorectalCancer #RegulatoryAffairs #Pharma #Healthcare

1

LABN Trending News: Gilead and Terray Therapeutics Announce Multi-Target Research Collaboration to Discover and Develop Novel Small Molecule Therapies https://lnkd.in/g3RAWEQm FOSTER CITY, Calif. & LOS ANGELES–(BUSINESS WIRE)–Gilead Sciences, Inc. (Nasdaq: GILD) and Terray Therapeutics, Inc. announced today that the companies have entered into a strategic collaboration to discover and develop novel, small molecule therapies across [...]

1

AbbVie Completes Acquisition of Cerevel Therapeutics 🔶 Cerevel's clinical-stage assets complement AbbVie's emerging #neuroscience pipeline and leading on-market brands in psychiatry, migraine and #parkinsonsdisease 🔶 Emraclidine, a potential best-in-class, next-generation antipsychotic, is in trials designed to be registration enabling for #schizophrenia 🔶 Cerevel is a strong strategic fit for AbbVie and has potential to meaningfully impact revenue into the next decade 🔶 AbbVie reaffirms previously issued 2024 full-year adjusted diluted EPS guidance range of $10.71-$10.91; reaffirms previously issued third-quarter adjusted diluted EPS guidance range of $2.92-$2.96 Full article in the comments ⬇

36

1 Comment

🚨 Bristol Myers Squibb's Karuna buyout pays off with FDA approval for novel schizophrenia med Cobenfy After decades of stagnation in the schizophrenia field, Bristol Myers Squibb’s $14 billion deal for Karuna Therapeutics has borne fruit with the approval of a promising new drug. BMS’ first-in-class drug KarXT - now dubbed Cobenfy - won a landmark FDA approval Thursday to treat adults with schizophrenia. The medicine represents the first antipsychotic that targets cholinergic receptors as opposed to dopamine receptors, the FDA noted in a release. Roughly 24 million people live with schizophrenia worldwide, with around 2.8 million people suffering from the ailment in the U.S., according to BMS. But just 1.6 million of those U.S. patients are treated, BMS’ chief medical officer, Samit Hirawat, M.D., said in an interview. That's due in large part to the hefty side effect burden of current schizophrenia medicines on the market, he explained. Among the patients who are treated, around 70% eventually go off their medicines because of that side effect burden. Side effects of current schizophrenia medicines include weight gain, movement disorders, excessive sedation and more, BMS’ chief commercialization officer, Adam Lenkowsky, added during the interview. By comparison, Cobenfy’s principal side effects are nausea, vomiting and constipation, which are transient and can be treated with common antiemetics, he explained. Full article from Fierce Pharma in the comments ⬇️ #schizophrenia #fdaapproval #neuroscience

37

5 Comments